SCHEMBL23726282

SCHEMBL23726282

COc1cc2ncnc(-c3ccc(NCCN)nc3)c2cc1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 2/20 0.74
KIT P10721 6/20 0.55
EGFR P00533 4/20 0.47
PRKD3 O94806 1/20 0.47
PRKCG P05129 1/20 0.47
PRKCB P05771 1/20 0.47
LCK P06239 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCH P24723 1/20 0.47
PRKCI P41743 1/20 0.47
ZAP70 P43403 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCQ Q04759 1/20 0.47
PRKCZ Q05513 1/20 0.47
PRKCD Q05655 1/20 0.47
PRKD1 Q15139 1/20 0.47
PDE10A Q9Y233 4/20 0.46
MAPK1 P28482 2/20 0.43
MEN1 O00255 1/20 0.43
STAT3 P40763 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23762391 0.85 ENPP1 (1.00) ENPP1KIT
SCHEMBL25656211 0.85 ENPP1 (0.54) ENPP1KITEGFRPRKD3PRKCG
Hydrochloric Acid SCHEMBL23726792 0.84 ENPP1 (0.98) ENPP1KIT
Hydrochloric Acid SCHEMBL30117275 0.84 ENPP1 (0.98) ENPP1KIT
SCHEMBL29055068 0.84 ENPP1 (0.64) ENPP1KITEGFRLCKPDE10A
SCHEMBL24510842 0.84 ENPP1 (0.68) ENPP1KITEGFRPDE10AMAPK1
SCHEMBL31502046 0.84 ENPP1 (0.68) ENPP1KITEGFRPDE10AMAPK1
Hydrochloric Acid SCHEMBL30080144 0.84 ENPP1 (0.71) ENPP1KITEGFRLCKPDE10A
Hydrochloric Acid SCHEMBL23726791 0.84 ENPP1 (0.71) ENPP1KITEGFRLCKPDE10A
SCHEMBL23727079 0.81 ENPP1 (0.77) ENPP1KITPDE10AMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100394-B1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2026-04-08 EP disclosed
CN-115362145-B External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof 斯汀格瑞治疗股份有限公司 2025-05-02 CN disclosed
US-20250092018-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2025-03-20 US disclosed
US-12152015-B2 Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof Stingray Therapeutics, Inc. (US) 2024-11-26 US disclosed
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2023-06-15 US disclosed
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF STINGRAY THERAPEUTICS INC (US) 2023-06-15 US disclosed
US-11591313-B2 Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof Stingray Therapeutics, Inc. (US) 2023-02-28 US disclosed
US-11591313-B2 Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof Stingray Therapeutics, Inc. (US) 2023-02-28 US disclosed
EP-4100394-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. (US) 2022-12-14 EP disclosed
CN-115362145-A Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitors and methods of use thereof 斯汀格瑞治疗股份有限公司 2022-11-18 CN disclosed
US-20210253556-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. 2021-08-19 US disclosed
US-20210253556-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. 2021-08-19 US disclosed
WO-2021158829-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF Stingray Therapeutics, Inc. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183212-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PPA1 ENPP1 1/4885KIT 4739/4885EGFR 3428/4885
US-11591313-B2 Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof ENPP1, ENPP3, PPA1 ENPP1 1/4885KIT 4739/4885EGFR 3428/4885
US-20210253556-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PPA1 ENPP1 1/4885KIT 4739/4885EGFR 3428/4885
US-20250092018-A1 INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF ENPP1, ENPP3, PDE7A ENPP1 1/4885KIT 4741/4885EGFR 4525/4885
US-12152015-B2 Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and methods of use thereof ENPP1, ENPP3, PPA1 ENPP1 1/4885KIT 4739/4885EGFR 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.